These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

988 related items for PubMed ID: 18372589

  • 1. [Potentialities of a serological method in diagnosis of atrophic gastritis].
    Pimenov SI, Makarenko EV.
    Ter Arkh; 2008; 80(2):15-21. PubMed ID: 18372589
    [Abstract] [Full Text] [Related]

  • 2. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study.
    Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agréus L.
    Scand J Gastroenterol; 2008; 43(12):1448-55. PubMed ID: 18663663
    [Abstract] [Full Text] [Related]

  • 3. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
    Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV.
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1666-71. PubMed ID: 17559360
    [Abstract] [Full Text] [Related]

  • 4. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.
    Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, Ishii H, Hibi T.
    Hepatogastroenterology; 2004 Nov; 51(59):1249-54. PubMed ID: 15362725
    [Abstract] [Full Text] [Related]

  • 5. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.
    Bölükbaş C, Bölükbaş FF, Ovünç O, Kiliç G, Dalay R, Güven H, Uras F, Yardimci TK, Sökmen MH, Agan AF, Pişkinpaşa N.
    Turk J Gastroenterol; 2006 Sep; 17(3):172-6. PubMed ID: 16941249
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study.
    Sipponen P, Ranta P, Helske T, Kääriäinen I, Mäki T, Linnala A, Suovaniemi O, Alanko A, Härkönen M.
    Scand J Gastroenterol; 2002 Jul; 37(7):785-91. PubMed ID: 12190091
    [Abstract] [Full Text] [Related]

  • 7. Morpho-functional comparisons in Helicobacter pylori-associated chronic atrophic gastritis.
    Pasechnikov VD, Chukov SZ, Kotelevets SM, Chabannaya TA.
    Rocz Akad Med Bialymst; 2005 Jul; 50():183-7. PubMed ID: 16358962
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Serological diagnosis of atrophic gastritis with a combination of pepsinogen I and II, gastrin-17 and anti-Helicobacter pylori antibodies].
    Valle Muñoz J, Artaza Varasa T, López Pardo R, Rodríguez Merlo R, Pérez Grueso MJ, Martín Escobedo R, Alcántara Torres M, Cuena Boy R, Carrobles Jiménez JM.
    Gastroenterol Hepatol; 2007 Dec; 30(10):567-71. PubMed ID: 18028850
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. GastroPanel® test for non-invasive diagnosis of atrophic gastritis in patients with dyspepsia.
    Masci E, Pellicano R, Mangiavillano B, Luigiano C, Stelitano L, Morace C, Viale E, Freschi M, Locatelli M, Ieri R, Cavallaro A, Testoni S, Testoni PA.
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):79-83. PubMed ID: 24632770
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Risk of gastric cancer dependent on serological markers of atrophic gastritis: cohort study].
    Reshetnikov OV, Openko TG, Simonova GI, Kurilovich SA, Maliushina SK, Ragino IuI, Voevoda MI.
    Vopr Onkol; 2012 Mar; 58(5):644-8. PubMed ID: 23600281
    [Abstract] [Full Text] [Related]

  • 16. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC, Kumar S, Krishnani N, Kumari N, Chourasia D, Tripathi S.
    Trop Gastroenterol; 2011 Mar; 32(4):292-8. PubMed ID: 22696910
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The non-invasive diagnosis of precancerous changes of stomach mucosa.
    Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Polyakova MB, Mernova VP.
    Rocz Akad Med Bialymst; 2004 Mar; 49():66-71. PubMed ID: 15631316
    [Abstract] [Full Text] [Related]

  • 20. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care.
    Germaná B, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, Comparato G, Carloni C, Bertiato G, Battiestel M, Papa N, Aragona G, Cavestro GM, Iori V, Merli R, Bertolini S, Caruana P, Franzé A.
    Dig Liver Dis; 2005 Jul; 37(7):501-8. PubMed ID: 15975537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.